Company intelligence / Profile preview
Da Zen Theranostics
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
Da Zen Theranostics has developed a proprietary platform using imaging dye-drug conjugates that enable precise detection and targeted delivery of chemotherapeutic agents to cancer cells. The lead candidate, DZ-002, has completed or is completing Phase I trials in patients with advanced solid malignancies or lymphoma. Early results indicate the approach can improve efficacy while reducing toxicity by confining therapy to tumor cells and aiding surgical resection through fluorescence guidance. The company plans to initiate Phase II trials at HOAG Cancer Center in early 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule-drug conjugates (including dye-drug conjugates)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Da Zen Theranostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Da Zen Theranostics.